NASDAQ: IPA - ImmunoPrecise Antibodies Ltd.

Altı ay boyunca karlılık: -33.52%
Temettü getirisi: 0.00%
Sektör: Healthcare

Promosyon programı ImmunoPrecise Antibodies Ltd.


Şirket hakkında ImmunoPrecise Antibodies Ltd.

ImmunoPrecise Antibodies Ltd., together with its subsidiaries, operates as a biotherapeutic research and technology company in Canada and internationally. It provides NonaVac DNA for complex protein classes, including GPCRs and ion channels; and Rapid Prime, a positive monoclonal antibodies for generating anti-idiotypic antibodies, and producing monoclonal antibodies against conformational epitopes. The company also offers syngeneic cell line for immunization and screening; and peptide production for subsequent antibody discovery campaign.

daha fazla ayrıntı
In addition, it provides B cell select platform which allows for the interrogation of animal antibody repertoire; screening of the immune repertoire of rabbits and chickens and select the desired antibody directly from the B cells; single step hybridoma, a semi-solid media to grow mouse and rat hybridomas; and DeepDisplay, a combination of transgenic animal platform and custom IPA phage display antibody selection. The company also offers phage display, a custom immune libraries from multiple species; and CAR development, an adaptable antibody which allows the inclusion of functional data early in the screening funnel. Further, it provides silico developability, a profiling toolset for antibody lead candidates; and vitro analytical tools for the study of various critical quality attributes. Additionally, the company offers LucinaTech, an antibody humanization to identify essential framework and CDR residues; antibody affinity maturation for therapeutic and diagnostic application; and antibody chimerization for cloning and production of variable antibody domain. It also provides Eurofins preclinical services; hybrid service model, a service model designed to reduce time and risk with custom technologies and applications; and breadth and depth to accelerate assay development, screening cascades, drug candidate validation, and new biotherapeutic concepts. The company was incorporated in 1983 and is headquartered in Victoria, Canada.

IPO date 2017-01-03
ISIN CA45257F2008
Industry Biotechnology
Sector Health Care
Валюта usd
Валюта отчета cad
Сайт https://www.ipatherapeutics.com
Цена ао 0.405
Günlük fiyat değişimi: -4.96% (0.405)
Haftalık fiyat değişimi: -1.76% (0.3918)
Aylık fiyat değişimi: -15.03% (0.453)
3 ayda fiyat değişimi: -4.56% (0.4033)
Altı ayda fiyat değişimi: -33.52% (0.579)
Yıllık fiyat değişimi: -72.51% (1.4)
3 yılda fiyat değişimi: -89.43% (3.64)
5 yılda fiyat değişimi: -10.07% (0.428)
Yılbaşından bu yana fiyat değişimi: -10.47% (0.4299)

Hafife alma

İsim Anlam Seviye
P/S 1.96 7
P/BV 1.41 9
P/E 0 0
EV/EBITDA -2.54 0
Toplam: 5.25

Yeterlik

İsim Anlam Seviye
ROA, % -39.44 0
ROE, % -59.26 0
Toplam: 0

Temettüler

İsim Anlam Seviye
Div yield, % 0 0
DSI 0 0
Toplam: 1.02

Görev

İsim Anlam Seviye
Debt/EBITDA -0.5961 10
Toplam: 9.6

Büyüme dürtüsü

İsim Anlam Seviye
karlılık Revenue, % 74.41 8
karlılık Ebitda, % 6165.75 10
karlılık EPS, % 130.51 10
Toplam: 9.6



Süpervizör İş unvanı Ödeme Doğum yılı
Dr. Jennifer Lynne Bath Ph.D. CEO, President & Non-Independent Director 1.02M
Dr. Ilse Roodink Chief Scientific Officer & Interim General Manager of IPA Europe, Oss 277.03k

Adres: Canada, Victoria, 3204–4464 Markham Street - Google haritalarda aç, Yandex haritalarını aç
Web sitesi: https://www.ipatherapeutics.com